CompletedNot Applicable

The Clinical Characteristics of the Patients With Choledocholithiasis Without Cholangitis

44 participantsStarted 2012-10-02

Plain-language summary

Laboratory change induced by common bile duct (CBD) stone is in general observed as the higher elevation of alkaline phosphatase (ALP) and gamma-glutamyl transpeptideas (ɤ-GT), in comparison to those of aspartate aminotransferase (AST) and alanine aminotransferase (ALT). However, some patients with CBD stone show the marked increased level of aminotransferase, which sometimes leads to misdiagnose those as liver disease caused by viral hepatitis, ischemia, and drug toxicity. The aim of this study is to investigate the clinicopathologic features of patients with CBD stones with the high level of aminotransferase in serum.

Who can participate

Age range20 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. patients were diagnosed with CBD stone under endoscopic retrograde cholangiopancreatography (ERCP)
✓. patients showing above 400 IU/L of aminotransferase when at the first admitted into hospital and the control groups is the patients displaying normal AST and ALT.

What they're measuring

clinicopathologic features of patients with CBD stones with the high level of aminotransferase

Timeframe: 1year

Trial details

NCT IDNCT02647593

SponsorGangnam Severance Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2013-10-01

View on ClinicalTrials.gov More Choledocholithiasis trials